Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02014909 | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors | PHASE1 | COMPLETED | 64 | — | — | Jan 1, 2014 | Jun 5, 2017 | Jul 24, 2017 | 5 | United States |
Continued assessment of safety
| Arm | Type | Description |
|---|---|---|
| KTN3379 | EXPERIMENTAL | KTN3379 |
| Part II, Arm A | EXPERIMENTAL | Combination of KTN3379 and cetuximab |
| Part II, Arm B | EXPERIMENTAL | Combination of KTN3379 and erlotinib |
| Part II, Arm C | EXPERIMENTAL | Combination of KTN3379 and vemurafenib |
| Part II, Arm D | EXPERIMENTAL | Combination of KTN3379 and trastuzumab |
| Name | Type | Description |
|---|---|---|
| KTN3379 | BIOLOGICAL | Single agent KTN3379 or in combination administered until unacceptable toxicity or progressive disease |
Major Inclusion Criteria: * Part I Histologically- or cytologically-confirmed advanced solid tumors that are refractory to standard therapy or for which no standard therapy exist. Part II Arm A have head and neck cancer or K-Ras wild type EGFR expressing colon cancer, Arm B, have non small cell lun...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |